Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
Spatial neglect is a common condition after stroke that causes difficulty noticing or responding to the left side of the body or space. This condition often reduces independence in daily activities such as eating, dressing, and moving around. Researchers are evaluating a new computerized prism adaptation PA treatment that uses a game-like approach called Peg-the-Mole PTM to improve symptoms of spatial neglect. The trial aims to test the feasibility and effectiveness of this treatment in both inpatient and home settings through a randomized, controlled, double-blind design. Participants will be randomly assigned to one of two groups an experimental group using 15-degree rightward deviating prism goggles or a placebo control group using 5-degree deviating goggles. Both groups will complete ten 15-minute sessions over about two weeks using the PTM game on an iPad. Treatment can take place in the hospital or at home depending on hospital stay length, and a hybrid model will allow continuation of therapy after discharge if needed. During the study, participants will be assessed before starting the treatment, immediately after finishing it, and one month later. Researchers will measure neglect severity and its impact on daily activities using various tests and scales. Feasibility will be tracked through treatment compliance and patient feedback after each session. This study will help determine if the gamified and portable PA treatment can be successfully used to help patients recover from spatial neglect after stroke.
Actively Recruiting
Researchers are evaluating whether a low-cost virtual reality VR motor rehabilitation platform can help improve upper limb motor recovery in adults who have had a first-time ischemic stroke with moderate to severe motor deficits. The study compares VR-based motor therapy with standard care to see if VR can offer better recovery and be a practical, acceptable treatment option for stroke patients. This pilot study is sponsored by the Nova Scotia Health Authority and focuses on both hospital and home settings. Participants are randomly assigned to receive either standard stroke rehabilitation or additional motor therapy using a VR headset with gamified exercises. The study includes both inpatient care during the acute stroke period and outpatient care at home, with VR treatment sessions supplementing usual rehabilitation. The intervention uses a Meta Quest virtual reality device to deliver customized motor exercises designed to improve upper limb function. During the study, participants will complete motor function and quality of life assessments at multiple time points, both in hospital and at home. Researchers will monitor treatment effectiveness up to one week after therapy ends in hospital and through day 47 for home treatment. They will also evaluate treatment feasibility by assessing motion sickness, attitudes towards technology, patient engagement, and barriers to using VR rehabilitation. The total participation time varies depending on inpatient or outpatient status, with detailed monitoring throughout the treatment period.